Navigation Links
KGI Professor Animesh Ray Granted Funding by the Department of Defense for Research on Lung Cancer Drug Resistance
Date:6/17/2016

The Department of Defense has recently approved funding for Dr. Animesh Ray’s research proposal titled “A novel approach to understand and prevent the evolution of drug resistant lung cancer cells: A feasibility study.” The study, which will focus on lung cancer drug resistance, aims to examine the emergence of therapy resistant forms of lung cancer using state-of-the-art advances in genomic technology.

The re-emergence of drug resistant lung cancers in patients who initially responded to the therapy is a major cause of death. While many lung cancer patients who exhibit the spread of cancer to other parts of the body do respond well to treatment with anti-cancer drugs, it has been documented that the cancer can return aggressively, having developed resistance to the drug(s) used to treat the original cancers. There is an urgent need to understand and prevent such re-emergence of drug resistant cancers.

Elaborating on the scope of this project, Dr. Ray said: “When lung cancers are targeted with an anti-cancer drug, the genome of the cancer cells, due to their robustness, can find ways to become resistant to drugs. The current research proposal aims to use next-generation DNA sequence technology coupled with CRISPR technology to address this problem. The hope is that this preliminary work will help discover a new approach to prevent the appearance of relapsed drug resistant cancer.”

The study will use an alternate paradigm for drug development, which aims to target and prevent the adaptation of cancer cells to drugs, with the goal to undercut the major factor for death related to lung cancer. This novel approach will include the use of a recently developed genome-wide gene-targeting technology coupled with massively parallel DNA sequencing, followed by computational modeling. If successful, this project’s findings should ultimately benefit patients who have been treated for metastatic lung cancers and who are the among the most vulnerable lung cancer patients to succumb to the disease; included among them are numerous veterans of the armed forces.

According to Dr. Ray, it is anticipated that these experiments, if successful, can lead to a new paradigm of cancer treatment, in which a novel class of drugs with relatively low toxicity can be developed (drugs that do not by themselves target a cancer cell’s ability to survive, but will target the adaptive strategies of drug-treated cancer cells). The major benefit is that these drugs are expected to be less toxic than current anti-cancer drugs. This proposal is an important step towards developing lung cancer treatment, in that it is the first articulation of this novel concept of cancer drug development.

The official funding start date for this study is June 15, 2016.

Dr. Ray has been a professor at KGI for 15 years. He noted that throughout his career he has always been interested in how genomes rearrange to evolve new functions. The idea of this research project is based on a National Science Foundation-supported previous study Dr. Ray completed in his lab on a model organism—baker’s yeast—that showed there exists a previously unappreciated degree of robustness in the genome to deleterious onslaughts.

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Lung Cancer Research Program under Award No. W81XWH-16-1-0170. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. In the conduct of research involving hazardous organisms or toxins, the investigator adheres to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Read the full story at http://www.prweb.com/releases/2016/06/prweb13497483.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Worcester Polytechnic Institute Professor Suzanne Scarlata Elected President of the Biophysical Society
2. Professor John T. Arnason Receives 2015 ABC Norman R. Farnsworth Excellence in Botanical Research Award
3. Worcester Polytechnic Institute Professor Receives the KEEN 2015 Outstanding Faculty Award
4. Engineering Researcher and Professor Uses Maplesoft Technology to Improve Labor Techniques and Study Energy Regeneration in Rehabilitative Devices
5. The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree
6. New Jersey Health Foundation Awards $50,000 Innovation Grant To Stevens Institute of Technology Associate Professor
7. UCI Professor Zhibin Guan Joins NuGene Advisory Board
8. Immunocore Appoints Professor Sir John Bell to its Board of Directors
9. Bioinformatics book by Waynesburg University professor published internationally
10. Professor Federico Rosei named to the Royal Society of Canada
11. Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... VINELAND, N.J. (PRWEB) , ... August 10, 2018 , ... ... or fracturing while under pressure. The Explosion Protection Chamber for High-Pressure NMR & ... a new level of safety to the laboratory. , High-pressure experiments have significantly ...
(Date:8/9/2018)... ... August 08, 2018 , ... ActX introduces GenoACT(sm), ... continually updated by a talented scientific team that includes geneticists, PharmD’s, genetic counselors, ... 1. Information on the medical impact of a patient’s genetic variants , 2. ...
(Date:8/9/2018)... , ... August 08, 2018 , ... Since their establishment ... biotechnology and with a team nearly double its’ size from last year, the company ... new OpenSPR turned heads and impressed crowds at a private product launch event ...
(Date:8/9/2018)... , ... August 09, 2018 , ... ... Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, ... The review article was published online on August 9, 2018 and will be ...
Breaking Biology Technology:
(Date:8/7/2018)... ... 2018 , ... Nanomedical Diagnostics , leading manufacturer of ... “Synthetic Molecules for Disruption of the Myc Protein-Protein Interface ” in the ... R100, described as a “ field-effect transistor (Bio-FET) platform ,” to produce a ...
(Date:8/2/2018)... ... 2018 , ... Dickinson Wright PLLC is pleased to announce ... Group Chair for the Pharmaceuticals and Biotechnology group of the Intellectual Property division. ... life sciences initiatives, and appreciate the opportunity to integrate this firm’s capabilities on ...
(Date:8/2/2018)... N.J. (PRWEB) , ... August 02, 2018 , ... ... sample management solutions to pharmaceutical and biotech companies, today announced that Mark Jara, ... 100 most inspiring people in the life sciences industry. Individuals named to PharmaVOICE ...
Breaking Biology News(10 mins):